PMLS Virtual Series 2022 – Precision Medicine Outside of Oncology

Welcome and Opening Remarks

Nigel Russell, Director of Events, GenomeWeb

Precision Drug Discovery for Chronic Diseases

Steve Gardner, PhD, Co-founder and Chief Executive Officer, PrecisionLife

In the last decade, fewer than 10% of the targets investigated in drug discovery programs have led to approved drugs. The ‘blockbuster’ discovery strategy does not work well for complex, chronic diseases, leading to expensive late-stage clinical trial failures, mainly due to inability to demonstrate clinical efficacy in patients.

A new precision medicine approach, driven by high-resolution patient stratification insights, goes beyond AI drug discovery to offer a faster, cheaper, and derisked opportunity to bring to market new medicines that address significant pockets of unmet medical need, maximizing the benefits of precision medicines for both drug inventors and patients.

In this presentation, you will learn how this new approach to precision medicine is pioneering the development of better, more personalized therapy options:

• Driving novel target discovery in areas of unmet clinical need
• Identifying new opportunities for existing drugs in novel indications
• Enabling more focused clinical trials to demonstrate efficacy and reduce time to market

Delivering Precision Diagnostics and Genomic Insights Combining Large Data and AI

Bob Vaughan, PhD, Head of Data, Congenica

With the explosion of genomic and phenomic data we present a clinically driven approach to combining large scale data and the predictive capabilities of Congenica’s AI technology to derive both rapid clinical diagnosis of rare disease and potential new avenues of pharmaceutical research.

The Power of AI-Based Computational Histopathology Methods to Improve Clinical Development Effectiveness

Eric Walk, MD, Chief Medical Officer, PathAI

• Understanding common challenges in traditional NASH scoring systems that can impact clinical trial success
• Introduction to PathAI’s AI-based histologic measurement for NASH (AIM-NASH) and how it has been used for accurate, reproducible endpoint assessment
• Discuss additional advances in pathology techniques including continuous scoring of liver biopsy staging and other exploratory features to more sensitively demonstrate drug effect and potentially predict disease progression
• Deriving insights into other disease areas through leveraged learnings from AI-based assessments of NASH histopathology